Radiology and Oncology

Anti-Cancer Agents

Anticancer drugs have a strong promising pipeline, high prevalence and incidence rate of the cancer, increased in government funding, spur in cancer awareness programs, developed healthcare infrastructure etc. are some of the factors propelling the growth of the market during the forecast period. Furthermore, prevalence of unhealthy lifestyle, acceptance of advanced cancer technology, rise in awareness in developed countries etc. are the factors attributed to the growth of market. However these medicines attract high cost, have major side effects which can restrain the growth of the global anticancer drugs market through 2025.

Anticancer drugs Market: Geographical and Competitive Dynamics: Geographically, the global anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region. The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.